Navigation Links
UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
Date:12/3/2007

55.8% of patients, for 5mg/day, 20mg/day and 50mg/day, respectively,

compared to 16.7% for placebo.

-- Produced seizure freedom rates of 7.7% for 20 mg-50 mg/day, 8% for

5mg/day and 1.9% for placebo over the treatment period.

Patients in the second study (Abstract 3.218) were randomized to receive 50 mg/day, 150 mg/day, or placebo, administered twice-daily without titration over the 12 week treatment period. The findings for the study's primary endpoint-reduction in weekly seizure frequency over placebo-were not statistically significant. However, an analysis of the study's secondary endpoints demonstrated a clear difference between placebo and the 50 mg/day dose:
-- The median difference versus placebo for the percent reduction from

baseline in seizure frequency per week was 22.5%.

-- There was at least a 50% reduction in weekly seizure frequency from

baseline in 39.6% of patients, compared with 23.1% for placebo.

-- Seizure freedom rates of 9.4% were seen for 50mg/day, compared with

1.9% for placebo.

Retention rates in both studies were high and similar to placebo, with up to 98% of patients in the treatment group completing the studies. The most commonly reported adverse events were nausea, vomiting, fatigue, nasopharyngitis, anorexia, convulsion, dizziness, headache, somnolence, and insomnia. A dose-response relationship was not observed for the majority of adverse events analyzed in the studies.

Phase III clinical trials of brivaracetam as adjunctive therapy in patients with refractory partial onset epilepsy are already underway. Nearly 1,300 epilepsy patients, ages 16-70, will take part in three multicenter, multinational phase III trials. Two randomized, double-blind, placebo- controlled studies are designed to evaluate the efficacy and safety of brivaracetam (5, 20 and 50 mg/day or 20, 50 and 100 mg/day) over 12 weeks in patients with partial onset epilepsy, no
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
(Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
(Date:1/22/2015)... January 22, 2015 JJsHouse.com is a famous ... Today, the business announces its latest collection of wedding ... “The most important issue is the wedding dress on your ... in a woman’s life. Every bride wants to find the ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... ANA, Calif., Jan. 9 Grubb & Ellis,Healthcare REIT, ... two-property medical office building portfolio in San Antonio and,the ... acquisition closed in,December 2008. , ... Pecan Valley Medical,Office Building consists of approximately 60,000 square ...
... , NEW YORK, Jan. 9 A ... of juvenile myelomonocytic leukemia (JMML), a very rare form ... cord blood from the National Cord Blood Program (NCBP) of ... Blood Center.Juvenile myelomonocytic leukemia generally affects children under the age ...
... Study found impairments were mild, but they could signal ... Adults with diabetes now have to worry about whether ... report that declines in mental function are accelerated among ... analysis, published in the January issue of Neuropsychology ...
... The University of Texas Health Science Center at Houston ... in a ground-breaking area of genetic study known as ... to discover why some people with known risk factors ... may have to do with the interplay between their ...
... Jan. 9 Blue Shield of California has ... manage the company,s rapid growth and pursue new strategic initiatives. ... spearhead the company,s success, Blue Shield chairman and CEO Bruce ... , Paul Markovich, ...
... A study published today in The,Journal of Occupational and ... price tag for lupus - including medical,expenditures, absence from ... per patient. The mean cost climbed to more than ... disease nephritis, as it,often is. That,s more than the ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Acquires Mountain Plains Portfolio in Texas 2Health News:Grubb & Ellis Healthcare REIT Acquires Mountain Plains Portfolio in Texas 3Health News:Grubb & Ellis Healthcare REIT Acquires Mountain Plains Portfolio in Texas 4Health News:Seventeen Months After Cord Blood Transplant - Child is Free of Signs of Cancer 2Health News:Diabetes Linked to Cognitive Problems 2Health News:UT leads $2.5 million training program in pioneering area of genetic research 2Health News:UT leads $2.5 million training program in pioneering area of genetic research 3Health News:Paul Markovich Named Chief Operating Officer of Blue Shield of California 2Health News:Paul Markovich Named Chief Operating Officer of Blue Shield of California 3Health News:Lupus is a Significant Cost to Employers, According to Thomson Reuters Study 2Health News:Lupus is a Significant Cost to Employers, According to Thomson Reuters Study 3
(Date:1/23/2015)... Inc. (ICBU) has repositioned itself as a holding company with ... in the hydroponic, hemp and medical marijuana sectors. By acquiring ... sector, and recently partnering with the Chippewa Tribe Nation to ... iMD is committing to bring its vision to the market ...
(Date:1/23/2015)... 2015   Leatt Corporation  (OTCQB: LEAT), a global developer, ... forms of sports, including extreme motor sports, and whose ... that the UISP Lega Motociclismo Lombardia, an Italian motocross ... wear a neck brace during its racing competitions.  ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Medical Group,s (FMG) subsidiaries, VasoStar Inc., Mentor, Ohio  today ... Frontier grant to further develop and commercialize a novel ... Occlusions (CTOs), in lieu of invasive open heart surgery ... VasoStar,s primary clinical development partner is the Cleveland ...
... July 20, 2011 Advanced Health Media (AHM), the ... solutions for the pharmaceutical industry, has named James Burgess ... assumes responsibility from Jeff Brady who has served as ... as its President for 9 years. James brings over ...
Cached Medicine Technology:Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 2Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 3Advanced Health Media Announces New CEO 2